We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.
- Authors
Jinling Bi; Haiyuan Liu; Yong Huang
- Abstract
The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed.
- Subjects
CANCER treatment; RENAL cell carcinoma; DRUG side effects; COMPUTED tomography; HAND-foot syndrome; CANCER invasiveness; DISEASE risk factors
- Publication
International Medical Case Reports Journal, 2017, Vol 10, p223
- ISSN
1179-142X
- Publication type
Case Study
- DOI
10.2147/IMCRJ.S137484